FDA Approves Bemotrizinol, First New US Sunscreen Filter Since the 1990s
![<![CDATA[Q&A: Skin Cancer Prevention Beyond Summer, With Jill Cowan, APRN, FNP-BC]]>](/media/97/97c736a8cd72f5f6.1280.webp)
The FDA has approved bemotrizinol (BEMT), the first new sunscreen filter cleared for the US market since the 1990s. Jill Cowan, APRN, FNP-BC, a dermatology nurse practitioner, calls it the development she is watching most closely in skin cancer prevention heading into the new year.
She laid out her reasoning in a Q&A with Dermatology Times marking Healthy Skin Month in November. "What makes this new organic chemical UV filter different from current market is the broad spectrum UVA and UVB coverage that it has," Cowan said. It is also photostable, and it increases the stability of avobenzone, a filter notoriously prone to degradation. Its larger molecular size decreases systemic absorption — a direct answer to the absorption concerns that have shadowed older chemical filters.
The takeaway: after roughly three decades, American patients may finally get a filter that European and Asian markets have long treated as standard.
Why does UV protection matter in November?
Because clouds do not stop it. "UV exposure does not stop in the summer," Cowan said. "It is the daily, cumulative UV exposure that increases the risk for skin cancer. Therefore, daily use of SPF is critical." Even on gloomy winter days, UV penetrates cloud cover, meaning skin stays susceptible even when patients feel nothing. Snow reflects UV, and exposure climbs with altitude — two winter-specific factors patients rarely hear about.
The takeaway: sunscreen is a daily habit, not a summer product.
Which screening opportunities get missed?
Cowan sees a recurring gap at first visits. When a new patient arrives with a spot of concern, she strongly recommends offering a full-body skin examination — especially if the patient has not had a skin check in years, or has never had one at all. Clinicians can inspect the sites patients cannot visualize themselves: the scalp, the ears, the back. Those three locations are where self-exams routinely fail.
The takeaway: a worried patient presenting with one lesion is a standing invitation to examine everything.
How do you turn sunscreen knowledge into habit?
Cowan's counseling starts with a simple question: what are your barriers to daily SPF? Patients frequently answer that they simply have not built the habit. Her fix is environmental — keep bottles in commonly visited spots such as the bathroom vanity, bedside table, the coffee table where car keys live, a purse, or a work desk. Convenience drives adherence.
For patients who dislike product texture, she asks whether they prefer something lightweight or more moisturizing, then hands over samples of various SPFs. Many of the sampled products are available at the local grocery store, which lowers the friction further.
The takeaway: match the product to the patient, and put it where they will see it.
Who is overlooked in screening?
Patients with deeper skin tones top Cowan's list. The reason is misinformation — the incorrect belief that these patients are not at risk for skin cancer. All patients, regardless of skin type, are at risk for melanoma, squamous cell carcinoma and basal cell carcinoma. The stakes are documented: per the American Academy of Dermatology, the largest study of racial differences in men with melanoma found that men with skin of color have the lowest survival rates, and patients with skin of color are more likely to be diagnosed with melanoma at advanced stages.
She flagged a second high-risk group: solid organ transplant recipients on immunosuppressants. At every skin check, she educates patients on what to monitor during self-skin exams.
The takeaway: risk tracks with skin type and immune status, not with skin tone alone.
With bemotrizinol now approved and AI-assisted lesion detection and evolving screening recommendations on the horizon, clinicians should prepare to field patient questions about the new filter's broad-spectrum coverage and reduced absorption in the year ahead.
Source: dermatologytimes.com
Daniel Okafor
Show full bio
Staff writer covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.